ALSO NOTED: Santarus inks licensing deal; NeurogesX reports positive data; and much more...

> San Diego-based Santarus will gain $15 million up front and up to $65 million in milestones in a licensing deal with Schering-Plough for a low-dose version of the heartburn drug Zegerid. Report

> NeurogesX announced positive results from a Phase III trial of Transacin (NGX-4010), a high-concentration trans-capsaicin dermal patch, in patients with post-herpetic neuralgia. Release

> Auxilium Pharmaceuticals has abandoned development of TestoFilm, a testosterone-replacement transmucosal-film product for the treatment of hypogonadism. Report

> EXACT Sciences, which makes colon cancer detection technology, is laying off 21 of its 44 employees in a bid to conserve cash as it seeks new approvals. Report

And Finally… Every year more than 700,000 Americans end up in hospital ERs after experiencing a drug reaction. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.